Navigation Links
R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
Date:3/10/2009

SAN FRANCISCO, March 10 /PRNewswire/ -- New statistics just released reveal that R&D investment in new medicines by the biopharmaceutical industry was $65.2 billion in 2008, an increase of 3 percent from 2007, according to a combined analysis conducted by Burrill & Company, a San Francisco based global leader in life sciences whose principal activities are in Venture Capital, Private Equity, Merchant Banking and Media and the Washington DC-based Pharmaceutical Research and Manufacturers of America (PhRMA).

PhRMA-member companies alone spent an estimated $50.3 billion on pharmaceutical R&D last year -- up 5 percent from the 2007 total of $47.9 billion in 2007, according to a PhRMA survey. The Burrill & Company analysis shows that non-PhRMA pharmaceutical research companies in the United States spent an estimated $14.9 billion on R&D last year, compared with $15.3 billion in 2007.

"This is the fifth year that we have joined with PhRMA to report industry-wide biopharmaceutical research and development expenditures," said G. Steven Burrill, CEO of Burrill & Company. "The growth in R&D investment shows the industry's commitment to support important advances in better medicines and new treatments for patients made by research scientists and physicians."

"America's biopharmaceutical companies are not immune to the challenges presented by our current economic crisis," said PhRMA President and CEO Billy Tauzin. "However, the important work that we do every day in the battle with disease cannot stop. The U.S. is the world's hotbed of medical innovation, and throughout the country, we remain committed today to finding tomorrow's cures, despite the incredible challenges that are posed by the current economy."

Record investment in R&D is leading America's pharmaceutical research and biotechnology companies toward record levels of clinical testing of new medicines. Today, th
'/>"/>

SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
2. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007
3. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
4. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
5. Eiger BioPharmaceuticals Raises $7.1 Million A Round
6. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
7. Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm
8. TechniKroms Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical
9. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
10. Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
11. Mach One Executes Definitive Agreement to Acquire Biopharmaceutical Design & Engineering Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Spartan Bioscience announced today that Health Canada ... It detects CYP2C19 genetic mutations in less than 60 ... RX CYP2C19 System is the first near-patient DNA test ... Due to the system’s ease of use, Health Canada ... professionals such as doctors, nurses, pharmacists, and laboratory technicians, ...
(Date:10/30/2014)... A new report, commissioned by BioCrossroads and conducted by ... at Indiana,s capital market and ... time frames: 1993 to 2002 and 2003 to 2013.  ... investment growth.  The Life Science Innovation Capital in ... innovation dollars as well as an increase in life ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 The ... by Type (High & Medium), Sub-type (Primary & ... Processing, Infrastructure & Transportation & Power Generation) - ... the GIS market with analysis and forecasting of ... Market Data Tables with 52 Figures spread through ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 New ... SoundConnect , an industry leading unified communication ... partners and agents to deliver cloud-based audio and ... growth opportunities. , With SoundConnect’s Q4 incentive ... twenty-five video and/or web conferencing licenses sold, now ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4SoundConnect Unveils Q4 Partner Incentives 2
... Data and User Customization -- BUDAPEST, Hungary, August 20, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... Confirms Clinical Efficacy and Safety of Radioembolisation Using... -- BRUSSELS, August 19, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... Silence Therapeutics plc (AIM: SLN), a leading international RNAi ... Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of ... license to develop and commercialise QPI-1002, a p53 temporary ... Quark is currently conducting a Phase II clinical ...
Cached Biology Technology:ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 2ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 3ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 4ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 5ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 6Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 2Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 3Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 4Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 5Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 6Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 7Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2
(Date:10/30/2014)... suite of technologies that can be used to enhance ... everything from search and rescue to service dogs to ... computer-mediated communication between humans and dogs that opens the ... and sending them clear and unambiguous cues in return," ... science at NC State and co-lead author of a ...
(Date:10/29/2014)... Research suggesting air pollutants released by unconventional oil and ... US is published today in the open access journal ... sulfide and formaldehyde were found. The study is the ... who live near production sites and could be used ... and gas come from reserves that do not readily ...
(Date:10/29/2014)... (October 29, 2014, Beaverton, OR) New research ... 11th International Conference in Houston, TX showed for ... eliminate HPV infection in women using a readily ... The study, presented by Dr. Judith A. Smith, ... Gynecology and Reproductive Sciences at The University of ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
... of Parkinson,s disease patients had insufficient levels of vitamin ... of Medicine. The fraction of Parkinson,s patients ... than patients with Alzheimer,s disease (41 percent) or healthy ... in the October issue of Archives of Neurology ...
... of their chimpanzee relatives, bonobo societyin which females enjoy ... of image. While chimpanzee males frequently band together to ... believed to restrict what meat they do eat to ... according to a study, reported in the October 14th ...
... of the brain can come under attack in patients with ... with an MS-like disease, the brain,s response to a protein ... cord or cerebellum that comes under fire. The studyfrom researchers ... and Washington University in St. Louiswill be published online on ...
Cached Biology News:Lack of vitamin D linked to Parkinson's disease 2Lack of vitamin D linked to Parkinson's disease 3Despite 'peacenik' reputation, bonobos hunt and eat other primates too 2
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... been developed for use with immunohistochemical ... nonspecific background staining due to endogenous ... peroxidase with hydrogen peroxide. This ... with additional novel components to further ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: